Advertisement
Advertisement

EVGN

EVGN logo

EVOGENE LTD.

0.75
USD
Sponsored
-0.03
-3.75%
May 08, 15:52 UTC -4
Closed
exchange

After-Market

0.75

0.00
+0.04%

EVGN Earnings Reports

Positive Surprise Ratio

EVGN beat 15 of 30 last estimates.

50%

Next Report

Date of Next Report
May 20, 2026
Estimate for Q1 26 (Revenue/ EPS)
$357.00K
/
-$0.27
Implied change from Q4 25 (Revenue/ EPS)
+13.69%
/
-55.74%
Implied change from Q1 25 (Revenue/ EPS)
-85.39%
/
-28.95%

EVOGENE LTD. earnings per share and revenue

On Mar 05, 2026, EVGN reported earnings of -0.61 USD per share (EPS) for Q4 25, missing the estimate of -0.26 USD, resulting in a -130.02% surprise. Revenue reached 314.00 thousand, compared to an expected 280.50 thousand, with a 11.94% difference. The market reacted with a -6.16% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 3 analysts forecast an EPS of -0.27 USD, with revenue projected to reach 357.00 thousand USD, implying an decrease of -55.74% EPS, and increase of 13.69% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Werewolf Therapeutics, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.29
Actual
-$0.28
Surprise
+3.68%
logo
argenx SE - ADR
Report Date
May 07, 2026 For Q1 26
Estimate
$5.47
Actual
$5.52
Surprise
+0.86%
logo
Arrowhead Research Corporation
Report Date
May 07, 2026 For Q2 26
Estimate
-$1.16
Actual
-$0.93
Surprise
+20.32%
logo
ImmunityBio, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.07
Actual
-$0.09
Surprise
-26.05%
logo
Stoke Therapeutics, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.84
Actual
-$0.79
Surprise
+6.34%
logo
ANI Pharmaceuticals, Inc.
Report Date
May 08, 2026 For Q1 26
Estimate
$1.33
Actual
$2.04
Surprise
+54.04%
logo
Harmony Biosciences Holdings, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
$0.72
Actual
$0.55
Surprise
-24.16%
logo
CytomX Therapeutics, Inc.
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.12
Actual
-$0.10
Surprise
+18.83%
logo
Tectonic Therapeutic, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$1.20
Actual
-$1.34
Surprise
-11.07%
logo
ALX Oncology Holdings Inc. Common Stock
Report Date
May 08, 2026 For Q1 26
Estimate
-$0.22
Actual
-$0.17
Surprise
+24.24%
FAQ
For Q4 2025, EVOGENE LTD. reported EPS of -$0.61, missing estimates by -130.02%, and revenue of $314.00K, 11.94% above expectations.
The stock price moved down -6.16%, changed from $0.84 before the earnings release to $0.79 the day after.
The next earning report is scheduled for May 20, 2026.
Based on 3 analysts, EVOGENE LTD. is expected to report EPS of -$0.27 and revenue of $357.00K for Q1 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement